Novavax, Inc. (NVAX)
10.12
+0.75
(+8.00%)
USD |
NASDAQ |
Sep 01, 16:00
10.17
+0.05
(+0.49%)
Pre-Market: 08:57
Novavax Free Cash Flow : -43.02M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -43.02M |
| March 31, 2026 | -97.62M |
| December 31, 2025 | -251.02M |
| September 30, 2025 | -384.71M |
| June 30, 2025 | -637.33M |
| March 31, 2025 | -198.19M |
| December 31, 2024 | -101.90M |
| September 30, 2024 | -112.35M |
| June 30, 2024 | -23.57M |
| March 31, 2024 | -514.43M |
| December 31, 2023 | -776.36M |
| September 30, 2023 | -730.38M |
| June 30, 2023 | -740.57M |
| March 31, 2023 | -756.33M |
| December 31, 2022 | -508.92M |
| September 30, 2022 | -727.81M |
| June 30, 2022 | -813.92M |
| March 31, 2022 | -489.18M |
| December 31, 2021 | 265.46M |
| September 30, 2021 | 453.65M |
| June 30, 2021 | 592.76M |
| March 31, 2021 | 575.37M |
| December 31, 2020 | -97.16M |
| September 30, 2020 | 49.46M |
| June 30, 2020 | 32.06M |
| Date | Value |
|---|---|
| March 31, 2020 | -110.30M |
| December 31, 2019 | -138.48M |
| September 30, 2019 | -160.30M |
| June 30, 2019 | -161.59M |
| March 31, 2019 | -171.38M |
| December 31, 2018 | -186.20M |
| September 30, 2018 | -176.60M |
| June 30, 2018 | -188.09M |
| March 31, 2018 | -161.45M |
| December 31, 2017 | -140.80M |
| September 30, 2017 | -167.39M |
| June 30, 2017 | -190.92M |
| March 31, 2017 | -245.94M |
| December 31, 2016 | -276.98M |
| September 30, 2016 | -237.10M |
| June 30, 2016 | -201.10M |
| March 31, 2016 | -149.15M |
| December 31, 2015 | -108.17M |
| September 30, 2015 | -107.15M |
| June 30, 2015 | -93.32M |
| March 31, 2015 | -88.65M |
| December 31, 2014 | -75.40M |
| September 30, 2014 | -65.53M |
| June 30, 2014 | -62.79M |
| March 31, 2014 | -60.99M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Moderna, Inc. | -1.244B |
| Merck & Co., Inc. | 16.06B |
| Pfizer Inc. | 10.99B |
| Recursion Pharmaceuticals, Inc. | -354.26M |
| Agenus, Inc. | -98.50M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -72.81M |
| Cash from Investing (Quarterly) | 34.90M |
| Cash from Financing (Quarterly) | 1.201M |
| Free Cash Flow Per Share (Quarterly) | -0.446 |
| Free Cash Flow to Equity (Quarterly) | -75.66M |
| Free Cash Flow to Firm (Quarterly) | -67.52M |
| Free Cash Flow Yield | -2.59% |